
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4893300/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?. Expert Opinion on Pharmacotherapy, 2023, 24, 135-143.	0.9	4
2	Men with COVID-19 die. Women survive. Maturitas, 2022, 158, 34-36.	1.0	9
3	Sexuality, pelvic floor/vaginal health and contraception at menopause. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2022, 81, 85-97.	1.4	4
4	Missed opportunities in contraceptive counselling: findings from a European survey-based study with simulated patient consultation. European Journal of Contraception and Reproductive Health Care, 2022, 27, 85-94.	0.6	3
5	Menopause and female sexual dysfunctions. Minerva Obstetrics and Gynecology, 2022, 74, .	0.5	8
6	Perimenstrual Asthma in Adolescents: A Shared Condition in Pediatric and Gynecological Endocrinology. Children, 2022, 9, 233.	0.6	4
7	Biallelic mutations in PSMC3IP are associated with secondary amenorrhea: expanding the spectrum of prematureÂovarian insufficiency. Journal of Assisted Reproduction and Genetics, 2022, 39, 1177-1181.	1.2	3
8	Premenstrual Syndrome and Premenstrual Dysphoric Disorder as Centrally Based Disorders. Endocrines, 2022, 3, 127-138.	0.4	7
9	Role of Estrogens in Menstrual Migraine. Cells, 2022, 11, 1355.	1.8	28
10	Medical Treatment of Female Sexual Dysfunction. Urologic Clinics of North America, 2022, 49, 299-307.	0.8	12
11	Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Faculty Reviews, 2022, 11, 11.	1.7	23
12	Provoked Vestibulodynia and Topical Treatment: A New Option. Healthcare (Switzerland), 2022, 10, 830.	1.0	7
13	Menopause: a cardiometabolic transition. Lancet Diabetes and Endocrinology,the, 2022, 10, 442-456.	5.5	64
14	Crohn's Disease and Female Infertility: Can Nutrition Play a Supporting Role?. Nutrients, 2022, 14, 2423.	1.7	2
15	Polycystic ovary syndrome and sexuality. Gynecological Endocrinology, 2022, 38, 535-536.	0.7	6
16	SARS oVâ€2, testosterone and frailty in males (PROTEGGIMI): A multidimensional research project. Andrology, 2021, 9, 19-22.	1.9	59
17	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine, 2021, 18, 849-867.	0.3	40
18	Vaginal Health: Insights, Views & Attitudes survey in Latin America (VIVA-LATAM): focus on Brazil. Climacteric, 2021, 24, 157-163.	1.1	2

#	Article	IF	CITATIONS
19	The European Vulvovaginal Epidemiological Survey (EVES). Impact of history of breast cancer on prevalence, symptoms, sexual function and quality of life related to vulvovaginal atrophy. Gynecological Endocrinology, 2021, 37, 78-82.	0.7	7
20	Vulvovaginal atrophy of menopause and its impact on sexual function in an Italian clinical cohort of post-menopausal women. Journal of Obstetrics and Gynaecology, 2021, 41, 290-297.	0.4	1
21	Microablative Fractional CO2 Laser for Vulvovaginal Atrophy in Women With a History of Breast Cancer: A Pilot Study at 4-week Follow-up. Clinical Breast Cancer, 2021, 21, e539-e546.	1.1	20
22	Menopause transition: a golden age to prevent cardiovascular disease. Lancet Diabetes and Endocrinology,the, 2021, 9, 135-137.	5.5	23
23	Prolactin as a neuroendocrine clue in sexual function of women across the reproductive life cycle: an expert point of view. Gynecological Endocrinology, 2021, 37, 490-496.	0.7	3
24	A core outcome set for vasomotor symptoms associated with menopause: the COMMA (Core Outcomes) Tj ETC	Qq0.0.0 rg 0.8	BT /Overlock
25	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Climacteric, 2021, 24, 533-550.	1.1	4
26	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Women's Health, 2021, 30, 474-491.	1.5	22
27	Clinical features of migraine with onset prior to or during start of combined hormonal contraception: a prospective cohort study. Acta Neurologica Belgica, 2021, , 1.	0.5	1
28	The Gynogram: A Multicentric Validation of a New Psychometric Tool to Assess Coital Pain Associated With VVA and Its Impact on Sexual Quality of Life in Menopausal Women. Journal of Sexual Medicine, 2021, 18, 955-965.	0.3	7
29	Impact of postmenopausal vaginal discomfort on sex and relationships in Brazil: the CLOSER survey. Climacteric, 2021, 24, 1-7.	1.1	0
30	What women think about menopause: An Italian survey. Maturitas, 2021, 147, 47-52.	1.0	17
31	Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study. Maturitas, 2021, 147, 34-40.	1.0	16
32	Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause, 2021, 28, 875-882.	0.8	48
33	A core outcome set for genitourinary symptoms associated with menopause: the COMMA (Core) Tj ETQq1 1 0.7	784314 rg 0.8	BT 19verlock
34	Insulin resistance and potential modulators of ovarian reserve in young reproductive-aged women with obesity and type 1 diabetes. Gynecological Endocrinology, 2021, 37, 823-830.	0.7	2
35	Efficacy and safety of prolonged-release hyaluronic acid derivative vaginal application in the postpartum period: a prospective randomised clinical trial. Annals of Medicine, 2021, 53, 1589-1597.	1.5	7
36	Quality of Life and Sexual Health. ISGE Series, 2021, , 93-103.	0.2	0

#	Article	IF	CITATIONS
37	The role of hormone therapy in urogenital health after menopause. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101595.	2.2	9
38	The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study. Journal of Obstetrics and Gynaecology, 2020, 40, 512-519.	0.4	2
39	Myeloperoxidase and lactoferrin expression in semen fluid: Novel markers of male infertility risk?. Immunobiology, 2020, 225, 151999.	0.8	2
40	Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Frontiers in Endocrinology, 2020, 11, 516.	1.5	76
41	The heat is on. Climacteric, 2020, 23, S1-S2.	1.1	4
42	Insomnia and menopause: a narrative review on mechanisms and treatments. Climacteric, 2020, 23, 539-549.	1.1	45
43	"50 Shades of sex―under hormonal contraception. Gynecological Endocrinology, 2020, 36, 753-754.	0.7	3
44	Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric, 2020, 23, 426-446.	1.1	121
45	The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause. Menopause, 2020, 27, 423-429.	0.8	15
46	HPV Infection Affects Human Sperm Functionality by Inhibition of Aquaporin-8. Cells, 2020, 9, 1241.	1.8	21
47	Gender Differences at the Onset of Autoimmune Thyroid Diseases in Children and Adolescents. Frontiers in Endocrinology, 2020, 11, 229.	1.5	18
48	Effectiveness of hyaluronate-based pessaries in the treatment of vulvovaginal atrophy in postmenopausal women. Climacteric, 2020, 23, 519-524.	1.1	16
49	Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under. European Journal of Contraception and Reproductive Health Care, 2020, 25, 98-105.	0.6	5
50	Viewing symptoms associated with Vulvovaginal Atrophy (VVA)/Genitourinary syndrome of menopause (GSM) through the estro-androgenic lens – Cluster analysis of a web-based Italian survey among women over 40. Maturitas, 2020, 140, 72-79.	1.0	7
51	Vulvo-Vaginal Atrophy (VVA). , 2020, , 105-111.		2
52	Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. Expert Review of Neurotherapeutics, 2020, 20, 313-317.	1.4	25
53	Vulvovaginal atrophy (VVA) in breast cancer survivors (BCS) is still an unmet medical need: results of an Italian Delphi Panel. Supportive Care in Cancer, 2020, 28, 2507-2512.	1.0	9
54	Talking about genital problems with women aged over 70. Maturitas, 2020, 142, 73-74.	1.0	2

#	Article	IF	CITATIONS
55	Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature. European Journal of Contraception and Reproductive Health Care, 2020, 25, 221-227.	0.6	20
56	Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2695-e2709.	1.8	140
57	Long-Term Consequences of Menopause. Endocrinology, 2020, , 335-347.	0.1	0
58	Long-Term Consequences of Menopause. Endocrinology, 2020, , 1-13.	0.1	4
59	Dietary underreporting in women affected by polycystic ovary syndrome: A pilot study. Nutrition and Dietetics, 2019, 76, 560-566.	0.9	9
60	Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. Frontiers in Endocrinology, 2019, 10, 561.	1.5	90
61	Testosterone for women: green light for sex, amber light for health?. Lancet Diabetes and Endocrinology,the, 2019, 7, 738-739.	5.5	5
62	Hormonally Related Headaches. ISGE Series, 2019, , 93-100.	0.2	0
63	Easy tools to screen Italian women suffering from migraine with and without aura in early reproductive age. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 242, 63-67.	0.5	3
64	Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM). Journal of Sexual Medicine, 2019, 16, 1681-1695.	0.3	45
65	Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study. Gynecological Endocrinology, 2019, 35, 453-459.	0.7	20
66	2017 ATA guidelines on the management of thyroid dysfunctions in pregnancy: what do OB/GYNs need to know?. Gynecological Endocrinology, 2019, 35, 276-279.	0.7	5
67	Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update. Ecancermedicalscience, 2019, 13, 909.	0.6	19
68	Sexuality in premature ovarian insufficiency. Climacteric, 2019, 22, 289-295.	1.1	36
69	Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas, 2019, 124, 55-61.	1.0	41
70	What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?. Expert Opinion on Pharmacotherapy, 2019, 20, 777-779.	0.9	7
71	The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey. Menopause, 2019, 26, 485-491.	0.8	72
72	An individualized approach to the management of vaginal atrophy in Latin America. Menopause, 2019, 26, 919-928.	0.8	4

#	Article	IF	CITATIONS
73	Clinical and histological findings in bladder pain syndrome/interstitial cystitis: The implication of time of symptoms. Journal of Clinical Urology, 2018, 11, 248-253.	0.1	0
74	Perspectives on counseling patients about menopausal hormone therapy: strategies in a complex data environment. Menopause, 2018, 25, 937-949.	0.8	13
75	Has flibanserin revolutionized the treatment of hypoactive sexual desire disorder or is there still room for more effective therapeutics?. Expert Opinion on Pharmacotherapy, 2018, 19, 421-423.	0.9	3
76	Couplepause: A New Paradigm in Treating Sexual Dysfunction During Menopause and Andropause. Sexual Medicine Reviews, 2018, 6, 384-395.	1.5	64
77	Male perception about the inconveniences associated with monthly bleeding for their partner – an international survey. European Journal of Contraception and Reproductive Health Care, 2018, 23, 1-11.	0.6	7
78	The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric, 2018, 21, 286-291.	1.1	100
79	Efficacy and tolerability of a spray formulation containing Visnadine in women self-reporting sexual symptoms: a randomized double-blind placebo-controlled pilot study. Journal of Endocrinological Investigation, 2018, 41, 729-737.	1.8	6
80	Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). Journal of Headache and Pain, 2018, 19, 76.	2.5	64
81	Sexual well-being after menopause: An International Menopause Society White Paper. Climacteric, 2018, 21, 415-427.	1.1	89
82	Vaginal Health: Insights, Views & Attitudes (VIVA-LATAM): results from a survey in Latin America. Climacteric, 2018, 21, 397-403.	1.1	19
83	Real-world experience of women using extended-cycle vs monthly-cycle combined oral contraception in the United States: the National Health and Wellness Survey. BMC Women's Health, 2018, 18, 22.	0.8	13
84	The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. Menopause, 2018, 25, 837-847.	0.8	105
85	CLarifying vaginal atrophy's impact On SEx and Relationships (CLOSER) survey in South Africa. Climacteric, 2017, 20, 49-54.	1.1	3
86	Macro-regional variation in attitudes toward and experiences of vulvar and vaginal atrophy among Italian post-menopausal women: a <i>post hoc</i> analysis of REVIVE survey data. Gynecological Endocrinology, 2017, 33, 389-394.	0.7	3
87	Missed pills: frequency, reasons, consequences and solutions. European Journal of Contraception and Reproductive Health Care, 2017, 22, 165-169.	0.6	25
88	Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases?. Climacteric, 2017, 20, 306-312.	1.1	80
89	The sexuological impact of hormonal contraceptives based on their route of administration. Gynecological Endocrinology, 2017, 33, 218-222.	0.7	13
90	Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Journal of Headache and Pain, 2017, 18, 108.	2.5	130

#	Article	IF	CITATIONS
91	Development and conceptual validation of a questionnaire to help contraceptive choice: CHLOE (Contraception: HeLping for wOmen's choicE). European Journal of Contraception and Reproductive Health Care, 2017, 22, 286-290.	0.6	7
92	Women's preferences for menstrual bleeding frequency in 12 European countries: the Inconvenience Due to Women's Monthly Bleeding (ISY) survey. European Journal of Contraception and Reproductive Health Care, 2017, 22, 268-273.	0.6	14
93	The inconvenience due to women's monthly bleeding (ISY) survey: a study of premenstrual symptoms among 5728 women in Europe. European Journal of Contraception and Reproductive Health Care, 2017, 22, 354-359.	0.6	10
94	Monurelle Biogel [®] vaginal gel in the treatment of vaginal dryness in postmenopausal women. Climacteric, 2017, 20, 467-475.	1.1	10
95	Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 14. Journal of Sexual Medicine, 2017, 14, 1463-1491.	0.3	69
96	Cycle control with an extended-regimen oral contraceptive combining levonorgestrel and ethinyl estradiol that includes continuous low-dose ethinyl estradiol instead of the traditional hormone-free interval. International Journal of Women's Health, 2017, Volume 9, 739-747.	1.1	2
97	Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy. Minerva Obstetrics and Gynecology, 2017, 69, 370-380.	0.5	8
98	Modulation of nociceptive threshold by combined hormonal contraceptives in women with oestrogen-withdrawal migraine attacks: a pilot study. Journal of Headache and Pain, 2016, 17, 70.	2.5	19
99	Women's preferences for menstrual bleeding frequency: results of the Inconvenience Due to Women's Monthly Bleeding (ISY) survey. European Journal of Contraception and Reproductive Health Care, 2016, 21, 242-250.	0.6	17
100	Efficacy, tolerability and safety of a new medical device, Monurelle Biogel ® vaginal gel, in the treatment of vaginal dryness: a randomized clinical trial in women of reproductive age. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 203, 82-88.	0.5	14
101	Female sexual dysfunction (FSD): Prevalence and impact on quality of life (QoL). Maturitas, 2016, 94, 87-91.	1.0	194
102	Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: Evidence from the European REVIVE survey. Maturitas, 2016, 91, 74-80.	1.0	30
103	The REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey in Europe: Country-specific comparisons of postmenopausal women's perceptions, experiences and needs. Maturitas, 2016, 91, 81-90.	1.0	47
104	Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group. Gynecological Endocrinology, 2016, 32, 602-606.	0.7	30
105	The American–European difference in vulvar and vaginal atrophy views: a lesson from the REVIVE Survey. Climacteric, 2016, 19, 252-255.	1.1	6
106	Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric, 2016, 19, 60-65.	1.1	25
107	Recovering sex drive in women — progress and opportunities. Nature Reviews Urology, 2016, 13, 67-68.	1.9	3
108	Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians. European Journal of Contraception and Reproductive Health Care, 2016, 21, 106-115.	0.6	41

#	Article	IF	CITATIONS
109	Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric, 2016, 19, 188-197.	1.1	157
110	Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunity. Reproductive Biology and Endocrinology, 2015, 13, 106.	1.4	23
111	Sexual function after fractional microablative CO ₂ laser in women with vulvovaginal atrophy. Climacteric, 2015, 18, 219-225.	1.1	190
112	Diurnal Variation of Plasma Brain-Derived Neurotrophic Factor Levels in Women with Functional Hypothalamic Amenorrhea. Neuroendocrinology, 2015, 101, 256-262.	1.2	5
113	Surgical treatment affects perceived stress differently in women with endometriosis: correlation with severity of pain. Fertility and Sterility, 2015, 103, 433-438.	0.5	22
114	To be or not to be in sexual desire: the androgen dilemma. Climacteric, 2015, 18, 672-674.	1.1	23
115	Update on management of genitourinary syndrome of menopause: A practical guide. Maturitas, 2015, 82, 308-313.	1.0	111
116	Effect of local estrogen therapy (LET) on urinary and sexual symptoms in premenopausal women with interstitial cystitis/bladder pain syndrome (IC/BPS). Gynecological Endocrinology, 2015, 31, 828-832.	0.7	20
117	The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric, 2015, 18, 233-240.	1.1	40
118	Effects of combined hormonal contraception on health and wellbeing: Women's knowledge in northern Italy. European Journal of Contraception and Reproductive Health Care, 2015, 20, 36-46.	0.6	15
119	Advances in pharmacotherapy for treating female sexual dysfunction. Expert Opinion on Pharmacotherapy, 2015, 16, 875-887.	0.9	57
120	Why are there no FDA-approved treatments for female sexual dysfunction?. Expert Opinion on Pharmacotherapy, 2015, 16, 1735-1738.	0.9	11
121	Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review. European Journal of Contraception and Reproductive Health Care, 2015, 20, 329-343.	0.6	31
122	Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?. Clinical Breast Cancer, 2015, 15, 413-420.	1.1	57
123	Characteristics of post-menopausal women with genitourinary syndrome of menopause: Implications for vulvovaginal atrophy diagnosis and treatment selection. Maturitas, 2015, 81, 462-469.	1.0	33
124	Robotic Single-Site Surgery for Female-to-Male Transsexuals: Preliminary Experience. Scientific World Journal, The, 2014, 2014, 1-4.	0.8	14
125	Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: a review of the literature. International Journal of Women's Health, 2014, 6, 711.	1.1	16
126	Use of and attitudes towards emergency contraception: A survey of women in five European countries. European Journal of Contraception and Reproductive Health Care, 2014, 19, 93-101.	0.6	39

#	Article	IF	CITATIONS
127	Nerve-Sparing Approach Reduces Sexual Dysfunction in Patients Undergoing Laparoscopic Radical Hysterectomy. Journal of Sexual Medicine, 2014, 11, 3012-3020.	0.3	33
128	Topiramate for migraine prevention in fertile women: Reproductive counseling is warranted. Cephalalgia, 2014, 34, 1097-1099.	1.8	7
129	Counseling and management of patients requesting subcutaneous contraceptive implants: proposal for a decisional algorithm. Gynecological Endocrinology, 2014, 30, 525-531.	0.7	8
130	Pharmacokinetic considerations for therapies used to treat interstitial cystitis. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 673-684.	1.5	5
131	A 12-week treatment with fractional CO ₂ laser for vulvovaginal atrophy: a pilot study. Climacteric, 2014, 17, 363-369.	1.1	264
132	Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey. Menopause, 2014, 21, 137-142.	0.8	106
133	Oral D-mannose in recurrent urinary tract infections in women: a pilot study. Journal of Clinical Urology, 2014, 7, 208-213.	0.1	39
134	Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy. Current Medical Research and Opinion, 2014, 30, 143-148.	0.9	28
135	Robotic Single Site Hysterectomy with Bilateral Salpingo-Oophorectomy in Female to Male Transsexualism. Journal of Sexual Medicine, 2014, 11, 313-313.	0.3	8
136	Maintaining sexuality in menopause. Post Reproductive Health, 2014, 20, 22-29.	0.3	23
137	In-vitro culture system for mesenchymal progenitor cells derived from waste human ovarian follicular fluid. Reproductive BioMedicine Online, 2014, 29, 457-469.	1.1	25
138	Multinational, multicentre, randomised, open-label study evaluating the impact of a 91-day extended regimen combined oral contraceptive, compared with two 28-day traditional combined oral contraceptives, on haemostatic parameters in healthy women. European Journal of Contraception and Reproductive Health Care, 2014, 19, 285-294.	0.6	7
139	Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric, 2014, 17, 3-9.	1.1	211
140	Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: A randomised, placebo-controlled, phase III trial. Maturitas, 2014, 78, 91-98.	1.0	113
141	Hormonal contraception in women with migraine: is progestogen-only contraception a better choice?. Journal of Headache and Pain, 2013, 14, 66.	2.5	47
142	Sexual dysfunction in obese women: Does obstructive sleep apnea play a role?. Sleep Medicine, 2013, 14, 252-256.	0.8	30
143	The CLOSER (<u>CL</u> arifying Vaginal Atrophy's Impact <u>O</u> n <u>SE</u> x and) Tj ETQq1 1 0.784314 rg Male Partners. Journal of Sexual Medicine, 2013, 10, 2232-2241.	gBT /Overlo 0.3	ock 10 Tf 50 118
144	Toward a new concept of "natural balance―in oral estroprogestin contraception. Gynecological Endocrinology, 2013, 29, 891-896.	0.7	11

#	Article	IF	CITATIONS
145	Validity of the Decreased Sexual Desire Screener for Diagnosing Hypoactive Sexual Desire Disorder. Journal of Sex and Marital Therapy, 2013, 39, 132-143.	1.0	24
146	Effect of Sex and Estrogens on Neuronal Activation in an Animal Model of Migraine. Headache, 2013, 53, 288-296.	1.8	39
147	The CLOSER survey: Impact of postmenopausal vaginal discomfort on relationships between women and their partners in Northern and Southern Europe. Maturitas, 2013, 75, 373-379.	1.0	62
148	Differences in sexual desire between women with clinical versus biochemical signs of hyperandrogenism in polycystic ovarian syndrome. Hormones and Behavior, 2013, 63, 65-71.	1.0	24
149	Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception, 2013, 88, 369-375.	0.8	52
150	Counseling on vaginal delivery of contraceptive hormones: implications for women's body knowledge and sexual health. Gynecological Endocrinology, 2013, 29, 1015-1021.	0.7	5
151	Change to Either a Nonandrogenic or Androgenic Progestin-Containing Oral Contraceptive Preparation is Associated with Improved Sexual Function in Women with Oral Contraceptive-Associated Sexual Dysfunction. Journal of Sexual Medicine, 2013, 10, 3069-3079.	0.3	53
152	Vaginal Health: Insights, Views & Attitudes (VIVA) survey - Canadian cohort. Menopause International, 2013, 19, 20-27.	1.6	16
153	The CLOSER survey: Impact of postmenopausal vaginal discomfort on women and male partners in the UK. Menopause International, 2013, 19, 69-76.	1.6	22
154	Vaginal health in the United States. Menopause, 2013, 20, 1043-1048.	0.8	152
155	Pharmacogenomics and sexuality: a vision. Climacteric, 2013, 16, 25-30.	1.1	18
156	Secondary Provoked Vestibulodynia in Sexually Active Women with Uncomplicated Recurrent Urinary Tract Infections. Journal of Sexual Medicine, 2013, 10, 2265-2273.	0.3	21
157	Impaired Outcome of Controlled Ovarian Hyperstimulation in Women with Thyroid Autoimmune Disease. Thyroid, 2013, 23, 1312-1318.	2.4	20
158	Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. International Journal of Women's Health, 2013, 5, 437.	1.1	180
159	Neuroendocrine aspects of migraine in women. Gynecological Endocrinology, 2012, 28, 37-41.	0.7	21
160	Impact of intravesical hyaluronic acid and chondroitin sulfate on bladder pain syndrome/interstitial cystitis. International Urogynecology Journal, 2012, 23, 1193-1199.	0.7	64
161	The use of hormone therapy for the maintenance of urogynecological and sexual health post WHI. Climacteric, 2012, 15, 267-274.	1.1	89
162	Headache and adverse pregnancy outcomes: a prospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 161, 140-143.	0.5	37

#	Article	IF	CITATIONS
163	Reproductive depression. Gynecological Endocrinology, 2012, 28, 42-45.	0.7	74
164	Transdermal Hormonal Therapy in Perimenstrual Migraine: Why, When and How?. Current Pain and Headache Reports, 2012, 16, 467-473.	1.3	17
165	Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Climacteric, 2012, 15, 36-44.	1.1	343
166	Understanding weight gain at menopause. Climacteric, 2012, 15, 419-429.	1.1	430
167	Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome. Urogynaecologia International Journal, 2012, 26, 8.	0.2	Ο
168	Sexual Function and Distress in Women Treated for Primary Headaches in a Tertiary University Center. Journal of Sexual Medicine, 2012, 9, 761-769.	0.3	26
169	Predictors of postmenopausal dyspareunia. Climacteric, 2012, 15, 636.	1.1	1
170	Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception, 2011, 83, 223-228.	0.8	66
171	Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. Clinical Endocrinology, 2011, 75, 378-381.	1.2	55
172	Interstitial Cystitis is Associated with Vulvodynia and Sexual Dysfunction—A Case-Control Study. Journal of Sexual Medicine, 2011, 8, 1726-1734.	0.3	63
173	Cigarette Smoking Decreases the Genital Vascularization in Young Healthy, Eumenorrheic Women. Journal of Sexual Medicine, 2011, 8, 1717-1725.	0.3	29
174	Moderate Alcohol Intake, Genital Vascularization, and Sexuality in Young, Healthy, Eumenorrheic Women. A Pilot Study. Journal of Sexual Medicine, 2011, 8, 2334-2343.	0.3	14
175	Headaches During Pregnancy. Current Pain and Headache Reports, 2011, 15, 289-294.	1.3	28
176	Impact of Chemotherapy and Hormone Therapy on Female Sexual Health. , 2011, , 525-534.		2
177	Female sexual dysfunction is more than just a hormonal problem. Climacteric, 2011, 14, 693.	1.1	0
178	Endocrine Aspects of Women's Sexual Function. Journal of Sexual Medicine, 2010, 7, 561-585.	0.3	85
179	3-D Volumetric and Vascular Analysis of the Urethrovaginal Space in Young Women With or Without Vaginal Orgasm. Journal of Sexual Medicine, 2010, 7, 1445-1453.	0.3	26
180	PCOS and Urethrovaginal Space: 3-D Volumetric and Vascular Analysis. Journal of Sexual Medicine, 2010, 7, 2755-2764.	0.3	19

#	Article	IF	CITATIONS
181	Effects of Surgical and Adjuvant Therapies for Breast Cancer on Sexuality, Cognitive Functions, and Body Weight. Journal of Sexual Medicine, 2010, 7, 1891-1900.	0.3	96
182	Validation of the Sexual Interest and Desire Inventory-Female in Hypoactive Sexual Desire Disorder. Journal of Sexual Medicine, 2010, 7, 3918-3928.	0.3	37
183	Management of hypoactive sexual desire disorder in women: current and emerging therapies. International Journal of Women's Health, 2010, 2, 167.	1.1	24
184	Cutoff Score of the Sexual Interest and Desire Inventory-Female for Diagnosis of Hypoactive Sexual Desire Disorder. Journal of Women's Health, 2010, 19, 2191-2195.	1.5	23
185	Menopause and sexual desire: the role of testosterone. Menopause International, 2010, 16, 162-168.	1.6	24
186	Migraine and reproductive life. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 303-322.	1.0	22
187	Hypoactive sexual desire disorder: can we treat it with drugs?. Sexual and Relationship Therapy, 2010, 25, 264-274.	0.7	2
188	Hormonal and psycho-relational aspects of sexual function during menopausal transition and at early menopause. Maturitas, 2010, 67, 78-83.	1.0	62
189	Women's voices in the menopause: Results from an international survey on vaginal atrophy. Maturitas, 2010, 67, 233-238.	1.0	249
190	Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine: a pilot study. Gynecological Endocrinology, 2010, 26, 773-779.	0.7	21
191	Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials. Gynecological Endocrinology, 2010, 26, 804-814.	0.7	59
192	Therapeutic options for postmenopausal female sexual dysfunction. Climacteric, 2010, 13, 103-120.	1.1	65
193	Local estrogens for quality of life and sexuality in postmenopausal women with cardiovascular disease. Climacteric, 2009, 12, 112-116.	1.1	2
194	Hormonal management of migraine at menopause. Menopause International, 2009, 15, 82-86.	1.6	19
195	Female Urinary Incontinence During Intercourse: A Review on an Understudied Problem for Women's Sexuality. Journal of Sexual Medicine, 2009, 6, 40-48.	0.3	93
196	Ultrasonographic and Doppler Findings of Subclinical Clitoral Microtraumatisms in Mountain Bikers and Horseback Riders. Journal of Sexual Medicine, 2009, 6, 464-468.	0.3	18
197	Continuing Medical Education: The Use of Estrogen Therapy in Women's Sexual Functioning (CME). Journal of Sexual Medicine, 2009, 6, 603-616.	0.3	93
198	The Impact of the Mid-Urethral Slings for the Treatment of Stress Urinary Incontinence on Female Sexuality. Journal of Sexual Medicine, 2009, 6, 1534-1542.	0.3	40

#	Article	IF	CITATIONS
199	Periovulatory Morphometric and Vascular Modifications of the Clitoris in Young Adult and Middle-Aged Women. A Pilot Study. Journal of Sexual Medicine, 2009, 6, 2707-2714.	0.3	10
200	Genistein Supplements Might Not Induce Clitoral Modifications in Postmenopausal Women: A Prospective, Pilot Study. Journal of Sexual Medicine, 2009, 6, 3132-3138.	0.3	6
201	The Role of 3-D Ultrasonography in the Evaluation of Menstrual Cycle-Related Vascular Modifications of the Clitoris. A Prospective Pilot Study. Journal of Sexual Medicine, 2009, 6, 2715-2721.	0.3	19
202	Migraine is a Risk Factor for Hypertensive Disorders in Pregnancy: A Prospective Cohort Study. Cephalalgia, 2009, 29, 286-292.	1.8	104
203	The effects of oestrogen on urogenital health. Maturitas, 2009, 63, 149-151.	1.0	39
204	Menopause and sexuality: Prevalence of symptoms and impact on quality of life. Maturitas, 2009, 63, 138-141.	1.0	229
205	Dietary intakes in infertile women a pilot study. Nutrition Journal, 2009, 8, 53.	1.5	18
206	LEI (Lack of tEstosterone Impact) survey in a clinical sample with surgical menopause. Climacteric, 2009, 12, 533-540.	1.1	19
207	Psychosexual well-being in women using oral contraceptives containing drospirenone. Functional Neurology, 2009, 24, 71-5.	1.3	6
208	Issues concerning the use of hormone replacement therapy and risk of fracture: a populationâ€based, nested caseâ€control study. British Journal of Clinical Pharmacology, 2008, 65, 123-129.	1.1	5
209	Insight into Urogynecologic Features of Women with Interstitial Cystitis/Painful Bladder Syndrome. European Urology, 2008, 54, 1145-1153.	0.9	45
210	Menstrual Cycle-Related Changes in Circulating Androgens in Healthy Women With Self-Reported Normal Sexual Function. Journal of Sexual Medicine, 2008, 5, 854-863.	0.3	59
211	Menstrual Cycle-Related Morphometric and Vascular Modifications of the Clitoris. Journal of Sexual Medicine, 2008, 5, 2853-2861.	0.3	40
212	PCOS, Sexuality, and Clitoral Vascularisation: A Pilot Study. Journal of Sexual Medicine, 2008, 5, 2886-2894.	0.3	49
213	Women's perception of sexuality around the menopause: Outcomes of a European telephone survey. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2008, 137, 10-16.	0.5	82
214	Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Annals of Oncology, 2008, 19, 150-155.	0.6	55
215	Use of the Italian translation of the Female Sexual Function Index (FSFI) in routine gynecological practice. Gynecological Endocrinology, 2008, 24, 214-219.	0.7	125
216	New attitudes to sexuality in the menopause: clinical evaluation and diagnosis. Climacteric, 2007, 10, 105-108.	1.1	66

#	Article	IF	CITATIONS
217	Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes. Maturitas, 2007, 57, 315-324.	1.0	22
218	Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8–9, 2007. Gynecological Endocrinology, 2007, 23, 436-444.	0.7	5
219	Hypoactive sexual desire disorder in postmenopausal women. Gynecological Endocrinology, 2006, 22, 318-323.	0.7	42
220	Attitudes, perceptions and knowledge about the vagina: the International Vagina Dialogue Survey. Contraception, 2006, 73, 493-500.	0.8	48
221	Clitoral circulation in postmenopausal women with sexual dysfunction: A pilot randomized study with hormone therapy. Maturitas, 2006, 55, 288-295.	1.0	43
222	Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. Menopause, 2006, 13, 818-825.	0.8	29
223	Diaries and Calendars for Migraine. A Review. Cephalalgia, 2006, 26, 905-916.	1.8	71
224	Sexual Function and Endocrine Profile in Fertile Women With Type 1 Diabetes. Diabetes Care, 2006, 29, 312-316.	4.3	122
225	Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Human Reproduction, 2005, 20, 3423-3428.	0.4	35
226	Headache is a risk factor for the onset of hypertension in pregnancy. American Journal of Obstetrics and Gynecology, 2005, 193, S178.	0.7	0
227	ORIGINAL RESEARCH—PATHOPHYSIOLOGY: Clinical Biologic Pathophysiologies of Women's Sexual Dysfunction. Journal of Sexual Medicine, 2005, 2, 4-25.	0.3	114
228	Validation of the McCoy Female Sexuality Questionnaire in an Italian Sample. Archives of Sexual Behavior, 2005, 34, 641-647.	1.2	42
229	Efficacy ofCimicifuga racemosaon climacteric complaints: A randomized study versus low-dose transdermal estradiol. Gynecological Endocrinology, 2005, 20, 30-35.	0.7	120
230	Menstrual cycle-related changes in plasma oxytocin are relevant to normal sexual function in healthy women. Hormones and Behavior, 2005, 47, 164-169.	1.0	197
231	Mutation analysis of two candidate genes for premature ovarian failure, DACH2 and POF1B. Human Reproduction, 2004, 19, 2759-2766.	0.4	82
232	Markers of local immunity in cervico-vaginal secretions of HIV infected women: implications for HIV shedding. Sexually Transmitted Infections, 2004, 80, 108-112.	0.8	34
233	Women's sexual dysfunction: a pathophysiological review. BJU International, 2004, 93, 1156-1164.	1.3	107
234	Characteristics of Menstrual and Nonmenstrual Attacks in Women with Menstrually Related Migraine Referred to Headache Centres. Cephalalgia, 2004, 24, 707-716.	1.8	188

#	Article	IF	CITATIONS
235	Physiology of Female Sexual Function: Animal Models. Journal of Sexual Medicine, 2004, 1, 237-253.	0.3	100
236	Sexual Dysfunction is Common in Women with Lower Urinary Tract Symptoms and Urinary Incontinence: Results of a Cross-Sectional Study. European Urology, 2004, 45, 642-648.	0.9	316
237	Women?s sexuality after menopause: What role for androgens?. Sexuality, Reproduction & Menopause, 2004, 2, 204-208.	1.0	1
238	Psychoneuroendocrine correlates of secondary amenorrhea. Archives of Women's Mental Health, 2003, 6, 83-89.	1.2	20
239	Course of Migraine During Pregnancy and Postpartum: A Prospective Study. Cephalalgia, 2003, 23, 197-205.	1.8	296
240	Electrical Stimulation (ES) in the Management of Sexual Pain Disorders. Journal of Sex and Marital Therapy, 2003, 29, 103-110.	1.0	52
241	Serum Allopregnanolone Levels Relate to FSFI Score During the Menstrual Cycle. Journal of Sex and Marital Therapy, 2003, 29, 95-102.	1.0	23
242	Clinical Study on the Dose-Effect Relationship of a Nifuratel-Nystatin Combination in the Treatment of Vulvo-vaginal Infections. Arzneimittelforschung, 2003, 53, 730-737.	0.5	3
243	Neuroendocrine Response to the Serotonin Agonist M-Chlorophenylpiperazine in Women with Menstrual Status migrainosus. Neuroendocrinology, 2003, 78, 52-60.	1.2	18
244	Role of testosterone in feminine sexuality. Journal of Endocrinological Investigation, 2003, 26, 97-101.	1.8	6
245	Clitoral Artery Blood Flow in Healthy Young Women: Preliminary Report on Menstrual Cycle and Hormonal Contraception. Journal of Sex and Marital Therapy, 2002, 28, 187-193.	1.0	15
246	Self-Reported Sexual Symptoms in Women Attending Menopause Clinics. Gynecologic and Obstetric Investigation, 2002, 53, 181-187.	0.7	50
247	Parkinson's disease and reproductive life events. Neurological Sciences, 2002, 23, s85-s86.	0.9	11
248	Hormone Supplementation Differently Affects Migraine in Postmenopausal Women. Headache, 2002, 42, 924-929.	1.8	69
249	Changes in Nociceptive Flexion Reflex Threshold Across the Menstrual Cycle in Healthy Women. Psychosomatic Medicine, 2002, 64, 621-626.	1.3	60
250	Course of primary headaches during hormone replacement therapy. Maturitas, 2001, 38, 157-163.	1.0	93
251	Serum allopregnanolone in women with postpartum "blues― Obstetrics and Gynecology, 2001, 97, 77-80.	1.2	97
252	Serum Allopregnanolone in Women With Postpartum "Blues― Obstetrics and Gynecology, 2001, 97, 77-80.	1.2	70

#	Article	IF	CITATIONS
253	Pituitary LH reserve suggests high risk of bulimia in amenorrheic women. Psychoneuroendocrinology, 2001, 26, 721-730.	1.3	3
254	Climacteric Complaints, Female Identity, and Sexual Dysfunctions. Journal of Sex and Marital Therapy, 2001, 27, 567-576.	1.0	9
255	Sexual disorders in Parkinson's disease. Functional Neurology, 2001, 16, 283-8.	1.3	2
256	Low-level exposure to methylmercury modifies muscarinic cholinergic receptor binding characteristics in rat brain and lymphocytes: physiologic implications and new opportunities in biologic monitoring Environmental Health Perspectives, 2000, 108, 29-33.	2.8	131
257	Serum Allopregnanolone Levels in Pregnant Women: Changes during Pregnancy, at Delivery, and in Hypertensive Patients. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2429-2433.	1.8	193
258	Stimulating Effect of HIV-1 Coat Protein gp120 on Corticotropin-Releasing Hormone and Arginine Vasopressin in the Rat Hypothalamus: Involvement of Nitric Oxide. Experimental Neurology, 2000, 166, 376-384.	2.0	36
259	Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. Maturitas, 2000, 37, 27-32.	1.0	38
260	Memory Functioning at Menopause: Impact of Age in Ovariectomized Women. Gynecologic and Obstetric Investigation, 1999, 47, 29-36.	0.7	136
261	Perineal floor efficiency in sexually potent and impotent men. International Journal of Impotence Research, 1999, 11, 153-157.	1.0	38
262	Expression and neuropeptidergic characterization of estrogen receptors (ER? and ER?) throughout the rat brain: Anatomical evidence of distinct roles of each subtype. , 1998, 36, 357-378.		525
263	Eating disorders and Axis I psychiatric comorbidity in amenorrheic women. , 1998, 24, 137-146.		15
264	Circulating Levels of Allopregnanolone in Humans: Gender, Age, and Endocrine Influences. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2099-2103.	1.8	332
265	Aging is associated with changes in allopregnanolone concentrations in brain, endocrine glands and serum in male rats. European Journal of Endocrinology, 1998, 138, 316-321.	1.9	88
266	Expression and neuropeptidergic characterization of estrogen receptors (ERα and ERβ) throughout the rat brain: Anatomical evidence of distinct roles of each subtype. , 1998, 36, 357.		3
267	Effect of Immune and Metabolic Challenges on the Luteinizing Hormone-Releasing Hormone Neuronal System in Cycling Female Rats: An Evaluation at the Transcriptional Level*. Endocrinology, 1997, 138, 1374-1384.	1.4	54
268	Effects of a Yeast-Based Dietary Supplementation on Premenstrual Syndrome. Gynecologic and Obstetric Investigation, 1997, 43, 120-124.	0.7	15
269	Is transrectal ultrasonography a reliable diagnostic approach in ejaculatory duct sub-obstruction?. Human Reproduction, 1997, 12, 2186-2191.	0.4	40
270	Premenstrual dysphoric disorder and eating disorders. Cephalalgia, 1997, 17, 25-28.	1.8	12

#	Article	IF	CITATIONS
271	Aging female brain: is there a change of adaptive stress?. Aging Clinical and Experimental Research, 1997, 9, 64-65.	1.4	0
272	Post-menopausal changes and dementing illness: Ovarian steroids as the causal link?. Aging Clinical and Experimental Research, 1997, 9, 66-67.	1.4	1
273	Pituitary-adrenal responses to dexamethasone and CRH administration in patients with untreated Parkinson's disease. Aging Clinical and Experimental Research, 1997, 9, 69-70.	1.4	0
274	Influence of the Estrous Cycle on c- <i>fos</i> and CRH Gene Transcription in the Brain of Endotoxin-Challenged Female Rats. Neuroendocrinology, 1997, 65, 29-46.	1.2	66
275	Bicuculline enhances the corticosterone secretion induced by lipopolysaccharide and interleukin-1α in male rats. Journal of Endocrinological Investigation, 1996, 19, 83-87.	1.8	6
276	Adrenergic and serotoninergic receptors mediate the immunological activation of corticosterone secretion in male rats. Gynecological Endocrinology, 1996, 10, 149-154.	0.7	11
277	Estrous cycle- and acute stress-related changes of rat ovarian immunoreactive corticotropin-releasing factor. Gynecological Endocrinology, 1996, 10, 75-82.	0.7	20
278	Stress-Induced Genetic Expression of a Selective Corticotropin-Releasing Factor-Receptor Subtype Within the Rat Ovaries: An Effect Dependent on the Ovulatory Cycle1. Biology of Reproduction, 1995, 53, 1417-1428.	1.2	48
279	Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. Journal of Neuroscience, 1995, 15, 2680-2695.	1.7	192
280	Ovulatory cycle influences the stimulatory effect of stress on the expression of corticotropin-releasing factor receptor messenger ribonucleic acid in the paraventricular nucleus of the female rat hypothalamus Endocrinology, 1995, 136, 4073-4083.	1.4	55
281	Evidence for a role of neurosteroids in modulation of diurnal changes and acute stress-induced corticosterone secretion in rats. Gynecological Endocrinology, 1995, 9, 1-7.	0.7	62
282	Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception, 1995, 51, 221-224.	0.8	146
283	Involvement of μ-opioid receptors in the modulation of pituitary-adrenal axis in normal and stressed rats. Journal of Endocrinological Investigation, 1995, 18, 1-7.	1.8	33
284	Corticotropin-releasing factor (CRF) and stress-related reproductive failure: The brain as a state of the art or the ovary as a novel clue?. Journal of Endocrinological Investigation, 1995, 18, 872-880.	1.8	7
285	Acute stress- or lipopolysaccharide-induced corticosterone secretion in female rats is independent of the oestrous cycle. European Journal of Endocrinology, 1994, 131, 535-539.	1.9	24
286	The neuroendocrine effects of sumatriptan, a specific ligand for 5-HT1-like receptors. Clinical Endocrinology, 1994, 40, 211-214.	1.2	10
287	Ontogeny of the circadian rhythm in medial basal hypothalamic ß-endorphin content in female rat. Journal of Endocrinological Investigation, 1994, 17, 697-701.	1.8	2
288	Pituitary and ovarian interleukin-1α content changes according to estrous cycle and acute stress exposure. Gynecological Endocrinology, 1994, 8, 259-264.	0.7	4

#	Article	IF	CITATIONS
289	Effect of chronic intermittent stress on rat pregnancy and postnatal development. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1993, 51, 41-45.	0.5	29
290	Hypothalamic amenorrhea: evidence for a central derangement of hypothalamic-pituitary-adrenal cortex axis activity. Fertility and Sterility, 1993, 59, 571-576.	0.5	45
291	Effect of naltrexone treatment on the treadmill exercise-induced hormone release in amenorrheic women. Journal of Endocrinological Investigation, 1992, 15, 839-847.	1.8	11
292	The brain as a target organ of gonadal steroids. Psychoneuroendocrinology, 1992, 17, 385-390.	1.3	48
293	Ritanserin in Menstrual Migraine and Premenstrual Complaints Prophylaxis. Cephalalgia, 1991, 11, 195-196.	1.8	2
294	Vulvo-vaginal atrophy. , 0, , 52-57.		1
295	Effect of Immune and Metabolic Challenges on the Luteinizing Hormone-Releasing Hormone Neuronal System in Cycling Female Rats: An Evaluation at the Transcriptional Level. , 0, .		16
296	Serum Allopregnanolone Levels in Pregnant Women: Changes during Pregnancy, at Delivery, and in Hypertensive Patients. , 0, .		46
297	Profile of Brazilian climacteric women: results from the Brazilian Menopause Study. Climacteric, 0, , 1-7.	1.1	0